BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Report Raises Concerns Over St. Jude Medical (STJ) Heart Device


11/21/2012 9:27:23 AM

A report on an inspection of a St. Jude Medical facility released Tuesday by federal officials found significant flaws in the company’s testing and oversight of a controversial heart device component, a copy of the document shows. The report may also raise questions about how St. Jude executives recently depicted the inspection’s contents to investors and others. The report by the Food and Drug Administration centered on the company’s handling of a product known as the Durata, a critical electrical wire that connects an implanted defibrillator to a patient’s heart. St. Jude uses a material called Optim to insulate the component and preserve its electrical integrity. But questions about the durability of Optim have arisen following the failure of another St. Jude lead that uses an earlier material and has since been recalled. In October, St. Jude filed a version of the inspection report with the Securities and Exchange Commission but blacked out several portions of the report that referred to the Durata. At the time, the company said it was redacting the report based on what it said was its "good faith interpretation" of how the F.D.A. would act when releasing the document in response to a Freedom of Information Act request.


   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES